Imaging synaptic density in the living human brain
The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Synaptic density in the living human brain was measured with positron emission tomography and a synaptic vesicle glycoprotein 2A tracer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo imaging of synaptic density is now possible using PET and [ 11 C]UCB-J - a radioligand that binds to the synaptic vesicle protein 2A (SV2A) 41 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [41]
In the citing paper
“the most common method to quantify synaptic density has been the quantification of pre-(e.g., synaptophysin [9], synapsin [8]) and post-synaptic (e.g., PSD-95 [10]) genes/proteins”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
In the citing paper
“there was also good correlation between SV2A and the “gold standard” pre-synaptic density marker synaptophysin in western blot and confocal microscopy experiments”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“Thus, it was decided that SV2A can be used as an alternative to synaptophysin for quantification of synapse density”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“quantification of radiotracer binding to SV2A does correlate with measures of synaptic vesicle number [8,9,69,70] and expression of other pre-synaptic proteins classically used in postmortem and in vitro work (e.g., synaptophysin, synapsin).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373 · cited 2×
“2 × 10(14) synapses per liter of brain tissue, as reported for the female human brain (42), and two to five SV2A copies per vesicle (31, 36), it can be estimated that there are 154 to 385 vesicles per synapse.”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Moreover, regional synaptic changes have been demonstrated in patients with autism (10), depression (11), or schizophrenia (12, 13).”
BackgroundWiedenmann, B., & Franke, W. W. (1985) · Cell · doi:10.1016/s0092-8674(85)80082-9 · Cited by 1,428 · cited 1×
“SYN is themost abundant synaptic vesicle protein (31) and is a widely used marker of synaptic density (32, 33), because it was one of the first characterized (29, 34) and cloned (35) vesicle membrane proteins.”
BackgroundLoss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146
Research works printed but not linked: 1
- 10.1097/01.wcb.0000033967.83623.34 · doi:10.1097/01.wcb.0000033967.83623.34 · Paper page
Cited by
Items 201–300 of 592
Carson, R. E., & Kuo, P. H. (2019) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2019.2912129 · Cited by 24
Self-citationBertoglio, D., Amhaoul, H., Goossens, J., Ali, I. Y., Jonckers, E., Bijnens, T., Siano, M., Wyffels, L., Verhaeghe, J. A. J., der Linden, A. V., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102701 · Cited by 24
Mikkelsen, J. D., Kaad, S., Aripaka, S. S., & Finsen, B. R. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.05.003 · Cited by 24
Mansur, A., Rabiner, E. A., Tsukada, H., Comley, R. A., Lewis, Y. L., Huiban, M., Passchier, J., & Gunn, R. N. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20928149 · Cited by 24
“The centrum semiovale was defined using the automated anatomic labelling (AAL) template as previously described.(13,14) PET images were registered to each subject’s MRI image and corrected for motion using frame-to-frame rigid-body registration.”
MethodMozersky, J. T., Hartz, S. M., Linnenbringer, E. L., Levin, L., Streitz, M. L., Stock, K., Moulder, K. L., & Morris, J. C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200993 · Cited by 28
“In our case, many of the research results being returned surpass clinical quality requirements [72-78], but they are not approved for clinical use.”
Lu, W., Zeng, L., Wang, J., Xiang, S., Qi, Y., Zheng, Q., Xu, N., & Feng, J. (2024) · National Science Review · doi:10.1093/nsr/nwae080 · Cited by 30
“…to the gray matter volume determined by voxel-based morphometry (VBM), the synaptic density for each voxel is proportional to the SV2A data [28 ,29 ] acquired from PET imaging, and the number of the excitatory synaptic connections bet ween t wo voxels is proportional to the track density…”
MethodNavacerrada, M. E. S., Bahri, M. A., Becker, G., Seret, A., Germonpré, C., Lemaire, C. F., Giacomelli, F., Miévis, F., Luxen, A., Salmon, É., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01488-7 · Cited by 24
From animal models to human individuality: Integrative approaches to the study of brain plasticity
Hille, M., Kühn, S., Kempermann, G., Bonhoeffer, T., & Lindenberger, U. (2024) · Neuron · doi:10.1016/j.neuron.2024.10.006 · Cited by 24
Bini, J., Naganawa, M., Nabulsi, N., Huang, Y. H., Ropchan, J. R., Lim, K., Najafzadeh, S., Herold, K. C., Cline, G. W., & Carson, R. E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197285 · Cited by 24
“We identified 6 potentially useful radioligands targeting 4 different receptor sites: 11C-raclopride, 11C-FLB457, and 11C-(1)-4-propyl9-hydroxynaphthoxazine (PHNO), and 11C-(1)-PHNO (D2/D3 receptors); 11C-DASB (serotonin transporter); 11C-AS247190 (11b-hydroxysteroid dehydrogenase type 1 (HSD1) enzyme inhibitor) (25);…”
BackgroundSelf-citationRaval, N. R., Gudmundsen, F., Juhl, M., Andersen, I. V., Speth, N., Videbæk, A., Petersen, I. N., Mikkelsen, J. D., Fisher, P. M., Herth, M. M., et al. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.715811 · Cited by 22
Synaptic Density in Early Stages of Psychosis and Clinical High Risk
Blasco, M. B., Aji, K. N., Ramos-Jiménez, C., Leppert, I. R., Tardif, C. L., Cohen, J. P., Rusjan, P., & Mizrahi, R. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3608 · Cited by 23
He, X., Chen, J., Zhong, Y., Cen, P., Shen, L., Huang, F., Wang, J., Jin, C., Zhou, R., Zhang, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60187-5 · Cited by 24
The Sexual Dimorphic Synapse: From Spine Density to Molecular Composition
Uhl, M., Schmeißer, M. J., & Schumann, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.818390 · Cited by 26
Moors, T. E., Mona, D., Luehe, S., Durán-Pacheco, G., Spycher, L., Mundigl, O., Kaluza, K., Huber, S., Hug, M. N., Kremer, T., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01382-z · Cited by 25
“In support of this in humans, in vivo positron emission tomography (PET) imaging of a synaptic vesicle glycoprotein 2A radioligand in the brain of healthy subjects showed reduced binding potential in the midbrain as compared to hippocampus and putamen [77].”
BackgroundGermino, M., Gallezot, J.-D., Yan, J., & Carson, R. E. (2017) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aa731f · Cited by 22
“[11C]UCB-J is a new tracer targeting the synaptic vesicle glycoprotein 2A [22] and can be used to measure synaptic density, relevant to a wide range of diseases including epilepsy and Alzheimer’s disease.”
BackgroundSelf-citationFuture Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 23
Digital Twin Brain: a simulation and assimilation platform for whole human brainPreprint
Lu, W., Zeng, L., Du, X., Zhang, W., Xiang, S., Wang, H., Wang, J., Ji, M., Hou, Y., Wang, M., et al. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2308.01241 · Cited by 28
“%) and inhibitory neurons (20%), each with their specific external connection ratio of 6/25, 14/25, and 16/125, respectively, according to the PET data [8], [9].”
BackgroundAutomated radiosynthesis of [11C]UCB‐J for imaging synaptic density by positron emission tomography
Milicevic Sephton, S., Miklovicz, T., Russell, J. J., Doke, A., Li, L., Boros, I., & Aigbirhio, F. I. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3828 · Cited by 20
“The radiosynthesis of [(11)C]UCB-J is based on the application of the palladium(0)-mediated Suzuki cross-coupling reaction between the carbon-11 methyliodide ([(11)C]CH3I) and trifluoroborate precursor 3 (Figure 1).(7,10,11,13,14) Initially explored method employed a more common Suzuki reacting partner, ie, the corres…”
BackgroundMethodInfluentialToyonaga, T., Fesharaki-Zadeh, A., Strittmatter, S. M., Carson, R. E., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.787404 · Cited by 20
Self-citationPET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Prolonged anesthesia alters brain synaptic architecture
Wenzel, M., Leunig, A., Han, S., Peterka, D. S., & Yuste, R. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023676118 · Cited by 23
Sukprakun, C., & Tepmongkol, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1083775 · Cited by 20
Hindley, N., Avila, A. S., & Henstridge, C. M. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1130198 · Cited by 22
“Moreover, SV2A PET has also been used in frontotemporal dementia (FTD), which is thought to exist on a disease spectrum with ALS, to study synaptic density changes in patients with behavioral variant FTD (Malpetti et al., 2023), and in carriers of a repeat expansion in the chromosome 9 open reading frame 72 (C9ORF72)…”
BackgroundInfluentialCurrent status of PET tracers for the early diagnosis of Alzheimer's disease
Li, Y., Liu, T., Zeng, Q., & Cui, M. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117546 · Cited by 20
Neema, M., Schultz, J. L., Langbehn, D. R., Conrad, A. L., Epping, E. A., Magnotta, V. A., & Nopoulos, P. (2024) · Annals of Neurology · doi:10.1002/ana.27046 · Cited by 21
“58 The antagonistic pleiotropy theory suggests that mHTT induces a leftward shift in the entire trajectory of brain growth and development, maturation, and aging (Fig.”
Tau Spread, Apolipoprotein E, Inflammation, and More
Gonzalez, B. L., Abud, E. M., Abud, A. M., Poon, W. W., & Gylys, K. H. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.001 · Cited by 20
Imaging Synaptic Density: A Different Look at Neurologic Diseases
Rabiner, E. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198317 · Cited by 20
“Hence, the recent development of PET ligands for the synaptic vesicle glycoprotein 2A (SV2A), a target present in most (if not all) presynaptic terminals (1), represents an exciting breakthrough in our ability to monitor the synaptic status in the brain of preclinical species (2) and humans (3).”
BackgroundInteraction of Approved Drugs with Synaptic Vesicle Protein 2A
Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700003 · Cited by 19
11C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults
Matuskey, D., Yang, Y., Naganawa, M., Koohsari, S., Toyonaga, T., Gravel, P., Pittman, B. P., Torres, K., Pisani, L., Finn, C., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02776-2 · Cited by 22
“Our research group ’ s introduction of the radiotracer 11 C-UCB-J now allows reliable in vivo synaptic density measurements of the brain [24, 25] with binding to synaptic vesicle glycoprotein 2A (SV2A), an essential membrane protein expressed in the vesicles of presynaptic nerve terminals of…”
Self-citationAlzheimer’s disease is getting easier to spot
Dolgin, E. (2018) · Nature · doi:10.1038/d41586-018-05721-w · Cited by 20
de Bartolomeis, A., Avagliano, C., Vellucci, L., D’Ambrosio, L., Manchia, M., D’Urso, G., Buonaguro, E. F., & Iasevoli, F. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.08.019 · Cited by 19
Bini, J., Holden, D., Fontaine, K. M., Mulnix, T., Lu, Y., Matuskey, D., Ropchan, J. R., Nabulsi, N., Huang, Y. H., & Carson, R. E. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00670-w · Cited by 19
Self-citationGlorie, D., Verhaeghe, J., Miranda, A., De Lombaerde, S., Stroobants, S., & Staelens, S. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00721-2 · Cited by 20
PET Imaging in Preclinical Anti-Aβ Drug Development
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U. H., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03277-z · Cited by 21
“SV2A is a presynaptic protein involved in neurotransmitter release and storage.”
BackgroundInfluentialHalff, E. F., Cotel, M.-C., Natesan, S., McQuade, R., Ottley, C. J., Srivastava, D. P., Howes, O. D., & Vernon, A. C. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113203 · Cited by 18
Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain
Mendoza-Torreblanca, J. G., García-Cruz, M. E., Sánchez-Cruz, I., Gomez-Gonzalez, B., Juárez-Méndez, S., & Gómez-Lira, G. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.004 · Cited by 18
Drake, L. R., Wu, Y., Naganawa, M., Asch, R., Zheng, C., Najafzadeh, S., Pracitto, R., Lindemann, M., Li, S., Ropchan, J., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266470 · Cited by 18
Self-citationFang, X. T., Volpi, T., Holmes, S. E., Esterlis, I., Carson, R. E., & Worhunsky, P. D. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1124254 · Cited by 18
“PET imaging with the SV2A radioligand 11C-UCB-J has been validated as an indirect measure of synaptic density and is sensitive to neuron-level alterations in multiple psychiatric and neurodegenerative diseases (Finnema et al., 2016; Chen et al., 2018; Holmes et al., 2019; Matuskey et al., 2020; Mecca et al., 2020; D’S…”
MethodSelf-citationContreras-García, I. J., Pichardo-Macías, L. A., Santana-Gómez, C. E., Sánchez-Huerta, K., Ramírez-Hernández, R., Gómez-González, B., Rocha, L., & Mendoza Torreblanca, J. G. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.023 · Cited by 18
Ni, R. (2021) · Pharmaceuticals · doi:10.3390/ph14111179 · Cited by 18
Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography
Chen, Z., Liao, G., Wan, N., He, Z., Chen, D., Tang, Z., Long, Z., Zou, G., Peng, L., Wan, L., et al. (2023) · Movement Disorders · doi:10.1002/mds.29395 · Cited by 19
“SV2A is ubiquitously expressed in all presynaptic vesicles of brain and currently serves as a synaptic density marker in vivo measurement with the development of SV2A-specific radioligand.(10,11) Specifically, neuronal loss and severe reduced synaptic density were observed in cerebellum and brainstem of spinocerebella…”
BackgroundSelf-citationSmart, K. A., Uribe, C., Desmond, K. L., Martin, S. L., Vasdev, N., & Strafella, A. P. (2023) · Molecular Imaging · doi:10.1155/2023/1855985 · Cited by 18
Jager, J. E. D., Boesjes, R., Roelandt, G. H. J., Koliaki, I., Sommer, I. E., Schoevers, R. A., & Nuninga, J. O. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105796 · Cited by 21
Neuroimaging brain growth charts: A road to mental health
Chen, L.-Z., Holmes, A. J., Zuo, X., & Dong, Q. (2021) · Psychoradiology · doi:10.1093/psyrad/kkab022 · Cited by 20
“However, inconsistent platforms will introduce systematic differences that distort the image information, lead to spurious results, and thus damage reliability severely (Focke et al., 2011; Chen et al., 2014).”
Julia Van der, A., Jager, J. E. D., van Dellen, E., Mandl, R. C. W., Somers, M., Boks, M. P., Sommer, I. E., & Nuninga, J. O. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.016 · Cited by 18
“Future studies could focus on quantifying changes in neuroplastic processes of hippocampal subfields after ECT (preferably on multiple timepoints), for example using positron emission tomography to quantify synaptic density (Finnema et al., 2016).”
BackgroundPET imaging of synaptic density in Parkinsonian disorders
Martin, S. L., Uribe, C., & Strafella, A. P. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25253 · Cited by 22
“Preliminary tracers utilized the 11 C radioisotope and 11 C- UCB-J showed superior pharmokinetics, including rapid and high brain uptake, reversible binding kinetics and highly specific binding to gray matter (Finnema et al., 2016; Nabulsi et al., 2016).”
BackgroundMethodβ-Adrenergic Signaling Promotes Morphological Maturation of Astrocytes in Female Mice
Rosenberg, M. F., Godoy, M. I., Wade, S. D., Paredes, M. F., Zhang, Y., & Molofsky, A. V. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.0357-23.2023 · Cited by 19
Whole brain neuronal abnormalities in focal quantified with proton MR spectroscopy
Kirov, I. I., Kuzniecky, R., Hetherington, H. P., Soher, B. J., Davitz, M. S., Babb, J. S., Pardoe, H., Pan, J. W., & Gonen, O. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.11.017 · Cited by 17
“The most likely scenario is that of multifocal injury, given previous imaging data (Doucet et al., 2016; Finnema et al., 2016; Hetherington et al., 2007), which do not support the assertion of homogeneous injury over the entire brain.”
PET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 21
Self-citationBertoglio, D., Halloin, N., Lombaerde, S. D., Jankovski, A., Verhaeghe, J. A. J., Nicaise, C., & Staelens, S. G. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263222 · Cited by 17
“These ligands, including the selective and high-affinity radioligand (11)C-labeled (4R)-1-[(3-methylpyridin-4-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one (UCB-J), have emerged as powerful tools to quantify synaptic density in vivo noninvasively (20,21).”
BackgroundPoirier, S. E., Kwan, B. Y. M., Jurkiewicz, M. T., Samargandy, L., Steven, D. A., Marti, A. S., Cheung, V. L. S., KHAN, A. R., Romsa, J. G., Prato, F. S., et al. (2020) · European Journal of Hybrid Imaging · doi:10.1186/s41824-020-00079-7 · Cited by 17
“Perhaps the use of novel PET tracers targeted to pathogenesis of epilepsy such as imaging reduced synaptic density using PET-ligands targeting the synaptic vesicle protein 2A (Finnema et al. 2016) as well as receptor imaging using PET tracers targeting serotonin and gammaaminobutyric acid (Sarikaya 2015; Galovic and K…”
MethodNeurochemical correlates of synapse density in a Huntington's disease mouse model
Zarate, N., Gundry, K., Yu, D., Casby, J., Eberly, L. E., Öz, G., & Gómez‐Pastor, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15714 · Cited by 16
Wang, Y.-T., Ashton, N. J., Servaes, S., Nilsson, J., Woo, M. S., Pascoal, T. A., Tissot, C., Rahmouni, N., Therriault, J., Lussier, F. Z., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00420-1 · Cited by 17
“Furthermore, the availability of a PET ligand to study synaptic density [9, 10] would be very valuable to further investigate brain regional associations of synaptic degeneration and provide insights into the mechanistic links between AD biomarkers and synaptic alterations in the living human…”
BackgroundSV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes
Snellman, A., Tuisku, J., Koivumäki, M., Wahlroos, S., Aarnio, R., Rajander, J., Karrasch, M., Ekblad, L. L., & Rinne, J. O. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14327 · Cited by 17
Brains for Dementia Research: The Importance of Cohorts in Brain Banking
Francis, P. T., Hayes, G. M., Costello, H., & Whitfield, D. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-0327-2 · Cited by 17
Night Watch on the Titanic: Detecting Early Signs of Epileptogenesis in Alzheimer Disease
Lam, A. D., & Noebels, J. L. (2020) · Epiliepsy currents/Epilepsy currents · doi:10.1177/1535759720964775 · Cited by 17
“53 Other PET ligands that assess specific metabolic pathways or neurotransmitter receptors relevant to MTLE in AD are under development.”
Zhou, B., Wang, R., Chen, M.-K., Mecca, A. P., O’Dell, R. S., van Dyck, C. H., Carson, R. E., Duncan, J. S., & Liu, C. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-87231-1_4 · Cited by 23
Self-citationRen, W., Ji, B., Guan, Y., Cao, L., & Ni, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.771982 · Cited by 18
“developed a fully automated registration method for OAT-MRI brain imaging data registration empowered by DL, which consists of (1) two U-net-like neural networks to segment OAT and MRI images (71) and (2) an adaptive neural network to transform these generated OAT/MRI masks (reference).”
BackgroundMethodInfluentialLopresti, B. J., Royse, S. K., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15615 · Cited by 16
Juengling, F. D., Wuest, F. R., Kalra, S., Agosta, F., Schirrmacher, R., Thiel, A., Thaiss, W. M., Müller, H., & Kassubek, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.890425 · Cited by 18
“The binding of the PET ligand 11C-UCB-J to SV2A has been demonstrated to quantitatively correlate and co-localize with synaptophysin (SYN), a key protein located in the preor postsynaptic neurons, using a combined in vivo–in vitro validation, furthering evidence for SV2A targeting PET tracers to serve as synaptic dens…”
MethodJensen, K. H. R., Dam, V. H., Ganz, M., Fisher, P. M., Ip, C.-T., Sankar, A., Marstrand-Joergensen, M. R., Ozenne, B., Osler, M., Penninx, B. W. J. H., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04618-x · Cited by 19
“SV2A is ubiquitously and homogeneously located in synapses across the brain and allows for the determination of SV2A binding and presynaptic density in the brain [69, 70].”
BackgroundLiu, Y., Zhao, H., Li, Q., Cui, H.-W., & Huang, G. (2022) · Aging and Disease · doi:10.14336/ad.2022.1211 · Cited by 22
“degeneration in the cerebrospinal fluid [93-95].”
Zhornitsky, S., Oliva, H. N. P., Jayne, L. A., Allsop, A. S., Kaye, A. P., Potenza, M. N., & Angarita, G. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197890 · Cited by 18
“A further limitation is that some of the markers reviewed herein are indirect estimates of synaptic density (166, 173, 174) and may only reflect synaptic density alterations to the extent that the gap between different amounts of these proteins within synapses and the actual (i.”
BackgroundHu, D., Ma, L., Song, Z.-G., Zheng, Z., Cheng, L., & Liu, M. (2024) · Chaos, Solitons & Fractals · doi:10.1016/j.chaos.2024.114546 · Cited by 14
Wang, X., Zhang, X., Liu, J., Zhang, J., Liu, C., Cui, Y., Song, Q., Hou, Y., Wang, Y., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01440-9 · Cited by 18
“Since SV2A is widely expressed at synapses [35] and it reflects synaptic density in the brain [14], we therefore suggest that it is the damage to synapses by APOE that leads to the reduction of SV2A.”
BackgroundSnellman, A., Ekblad, L. L., Koivumäki, M., Lindgrén, N., Tuisku, J., Perälä, M., Kallio, L., Lehtonen, R., Saunavaara, V., Saunavaara, J. P., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.826423 · Cited by 17
Luppi, A. I., Rosas, F. E., Noonan, M. P., Mediano, P. A. M., Kringelbach, M. L., Carhart-Harris, R. L., Stamatakis, E. A., Vernon, A. C., & Turkheimer, F. (2022) · The Neuroscientist · doi:10.1177/10738584221138032 · Cited by 15
“Postmortem tissue analyses (Jacobs and others 2001) and in vivo imaging (Finnema and others 2016; Shafee and others 2015) have demonstrated that prefrontal and association cortices exhibit the highest synaptic density for the whole of the neocortex and the lowest myelin density.”
BackgroundBourne, K. Z., Natarajan, C., Perez, C., Tumurbaatar, B., Taglialatela, G., & Krishnan, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-54974-6 · Cited by 17
Preliminary evidence for preserved synaptic density in late-life depression
Vande Casteele, T., Laroy, M., Van Cauwenberge, M., Koole, M., Dupont, P., Sunaert, S., Van den Stock, J., Bouckaert, F., Van Laere, K., Emsell, L., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02837-8 · Cited by 14
“…density might therefore shed light on potential neurodegenerative patterns in LLD. Quantifying synaptic density in humans in vivo recently became possible with the advent of radioligands targeting the synaptic vesicle glycoprotein 2A (SV2A), a ubiquitous presynaptic transmembrane protein [20].”
BackgroundDendritic spines and their role in the pathogenesis of neurodevelopmental and neurological disorders
Akhgari, A., Michel, T. M., & Vafaee, M. S. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0151 · Cited by 15
“…quanti fi cation have become essential tools for early detection, staging, and prognosis of dendritic spine-related diseases; PET imaging of synaptic vesicle glycoprotein 2A (SV2A) has been developed as the fi rst-in-class noninvasive method to measure synaptic density in vivo (Finnema et al. 2016).”
MethodAn In Vivo High-Resolution Human Brain Atlas of Synaptic Density
Johansen, A., Beliveau, V., Colliander, E., Raval, N. R., Dam, V. H., Gillings, N., Aznar, S., Svarer, C., Plavén‐Sigray, P., & Knudsen, G. M. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1750-23.2024 · Cited by 17
Improved synthesis of SV2A targeting radiotracer [11C]UCB-J
Rokka, J., Schlein, E., & Eriksson, J. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0080-5 · Cited by 16
Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain
Thomsen, M. B., Schacht, A. C., Alstrup, A. K. O., Jacobsen, J., Lillethorup, T. P., Bærentzen, S. L., Noer, O., Orłowski, D., Elfving, B., Müller, H. K., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01506-8 · Cited by 15
In vivo study sheds new light on the dendritic spine pathology hypothesis of schizophrenia
Li, W., Lv, L., & Luo, X. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01449-2 · Cited by 14
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Self-citationLi, B., Chen, H., Zheng, Y., Xu, X., You, Z., Huang, Q., Huang, Y. H., Guan, Y., Zhao, J., Liu, J., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06862-z · Cited by 15
“The SV2A radioligand was developed to quantify synap - tic density in the living human brain [35].”
Self-citationLongitudinal Synaptic Density PET with 11C‐UCB‐J 6 Months After Ischemic Stroke
Michiels, L., Thijs, L., Mertens, N., Coremans, M., Vandenbulcke, M., Verheyden, G., Koole, M. J. B., Laere, K. V., & Lemmens, R. (2022) · Annals of Neurology · doi:10.1002/ana.26593 · Cited by 14
AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems
Mecca, A. P. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.04.003 · Cited by 15
Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET
Rossano, S. M., Toyonaga, T., Bini, J., Nabulsi, N., Ropchan, J. R., Cai, Z., Huang, Y. H., & Carson, R. E. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00464-0 · Cited by 15
“Synaptic vesicle glycoprotein 2A (SV2A) is the target of interest for novel PET radiotracers, and imaging with this ligand can assess synaptic density in the living brain [8], as SV2A exists in presynaptic vesicles ubiquitously across the brain [9].”
BackgroundSelf-citationLi, R., Xiao, L., Han, H., Long, H., Liao, W., Yang, Z., Zhu, H., Wang, X., Zou, T., Huang, Y., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07054-5 · Cited by 14
“A limited number of studies have measured the in vivo synaptic density using PET imaging and found decreased SV2A binding in the ipsilateral hippocampus and the mesial temporal lobe in TLE patients [19, 20].”
InfluentialSelf-citationImaging Synaptic Density in Aging and Alzheimer Disease with [ 18 F]SynVesT-1
Giorgio, J., Soleimani‐Meigooni, D. N., Janabi, M., Baker, S. L., Chen, X., Toueg, T. N., Weimer, R. M., Zinnhardt, B., Green, A., Rabinovici, G. D., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269005 · Cited by 14
“However, additional blocking studies using a different antiepileptic targeting SV2A, levetirace-tam, reported a 12% – 22% reduction in [ 11 C]UCB-J uptake within the centrum semiovale ( 3 , 30 ); this fi nding was subsequently replicated using [ 18 F]SynVesT-1 PET ( 5 ).”
Synaptic density in aging mice measured by [18F]SynVesT-1 PET
Xiong, M., Roshanbin, S., Sehlin, D., Hansen, H. D., Knudsen, G. M., Rokka, J., Eriksson, J., & Syvänen, S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120230 · Cited by 13
“Still, the first-generation ligand [ 11 C]UCB-J is the most widely used in clinical studies so far (Andersen et al., 2021; Finnema et al., 2016; Holmes et al., 2019; Mecca et al., 2022).”
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 13
Erbb4Deletion From Inhibitory Interneurons Causes Psychosis-Relevant Neuroimaging Phenotypes
Kiemes, A., Navacerrada, M. E. S., Kim, E., Randall, K., Simmons, C., Gonzalez, L. R., Petrinovic, M. M., Lythgoe, D. J., Rotaru, D., Censo, D. D., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac192 · Cited by 12
Navacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 13
“This protein is critical for the adequate functioning of the central nervous system, acting as a modulator of synaptic transmission [2,3].”
BackgroundSelf-citationOnwordi, E. C., Whitehurst, T., Shatalina, E., Carr, R., Mansur, A., Arumuham, A., Osugo, M., Marques, T. R., Jauhar, S., Gupta, S., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03269-8 · Cited by 11
“We used the CS, a white matter region containing low levels of SV2A and showing low [ 11 C]UCB-J uptake, as a reference region to calculate [ 11 C]UCB-J DVR as our PET outcome measure [31].”
Nussbaumer, J., Barve, A., Zufferey, V., Espourteille, J., Kirabali, T., Konietzko, U., Razansky, D., Rominger, A., Nordberg, A. K., Buée, L., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00508-2 · Cited by 12
“Positron emission tomography (PET) using SV2A radioligands [ 11 C]UCB-J, [ 18 F]UCB-H, [ 18 F]SynVesT-1, and [ 18 F]SynVesT-2 [20–26] has been developed for in vivo imaging.”
Kong, Y., Zhang, S., Huang, L., Zhang, C., Xie, F., Zhang, Z., Huang, Q., Jiang, D., Li, J., Zhou, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731114 · Cited by 13
Quantification of PET infusion studies without true equilibrium: A tissue clearance correction
Hillmer, A. T., & Carson, R. E. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19850000 · Cited by 11
“Equations (5) and (6) generate relationships between VT(A) and a corrected VT if and 1 or k2 are known.”
BackgroundResultSelf-citationPerspectives of brain imaging with PET systems
Majewski, S. (2021) · Bio-Algorithms and Med-Systems · doi:10.1515/bams-2021-0178 · Cited by 11
Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)
Rossano, S. M., Toyonaga, T., Berg, E., Lorence, I., Fowles, K., Nabulsi, N., Ropchan, J. R., Li, S., Ye, Y., Felchner, Z., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05825-6 · Cited by 13
“The positive, significant correlation between in vivo regional SV2A PET measures and ex vivo regional SV2A concentrations was expected, as previous work by our group has shown agreement between in vivo SV2A PET measures and ex vivo SV2A protein concentration in the adult baboon brain [20].”
BackgroundResultSelf-citationApplication of Neuroimaging in the Diagnosis and Treatment of Depression
Arslan, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_5 · Cited by 13
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity
Olson, D. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231054 · Cited by 13
Laroy, M., Casteele, T. V., Cauwenberge, M. G. A. V., Koole, M. J. B., Dupont, P. J., Sunaert, S. G., den Stock, J. V., Sienaert, P. A., Laere, K. V., Vandenbulcke, M., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.04.020 · Cited by 11
“Due to its SV2A affinity and distribution volume, the 11 C-UCB-J tracer, serves as a reliable marker for assessing synaptic density in vivo [5].”
BackgroundDiFilippo, A. H., Jonaitis, E. M., Ennis, G. E., McVea, A. K., McLachlan, M., Bettcher, B., Schulz, N., Pasquesi, M., Davenport‐Sis, N. J., Thor, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70321 · Cited by 11
Schifani, C., Hafizi, S., Silva, T. M. S., Watts, J. J., Khan, M. S., & Mizrahi, R. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1396205 · Cited by 12
“A first evaluation in a patient population with temporal lobe epilepsy indicated a significant reduction of [11C]UCB-J binding co-localized with the mesial temporal lobe sclerosis, confirming that [11C]UCB-J PET is sensitive to synaptic loss (Finnema et al., 2016).”
BackgroundMethodInfluentialvan Aalst, J., Jennen, L., Demyttenaere, K., Sunaert, S. G., Koole, M. J. B., Ceccarini, J., & Laere, K. V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.739356 · Cited by 10
“As the field of in vivo synaptic density imaging is still very young (12), no other studies investigating the effects of any behavioral/physical interventions on synaptic density in humans have been published so far.”
BackgroundBeyond monoamines: II. Novel applications for PET imaging in psychiatric disorders
Royse, S. K., Lopresti, B. J., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15657 · Cited by 26
Sun, C., Revilla, E. M., Zhang, J., Fontaine, K. M., Toyonaga, T., Gallezot, J., Mulnix, T., Onofrey, J. A., Carson, R. E., & Lu, Y. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119678 · Cited by 11
“As shown in Figure 8a for one real human study, frequent and large in magnitude changes were observed in the COD trace (red), which indicated that large and frequent motions occurred during the 35-60 min post-injection of an HRRT [(11)C]UCB-J synaptic density study [27], [31].”
MethodSelf-citationScreening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI
Prato, F. S., Pavlosky, W. F., Foster, S. C., Thiessen, J. D., & Beaujot, R. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180098 · Cited by 11
“This would also improve detection of non-diffuse disease as would be the case for the detection of small regions of epileptic focus in occult epilepsy [35] using 18FDG or disruptions of synaptic density in neurodegenerative diseases [27].”
Background
Metadata
- Authors
- Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D. D., Mercier, J., Hannestad, J., Huang, Y., & Carson, R. E.
- Affiliations
- Yale University (US)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Finnema, Sjoerd J.
- Hannestad, Jonas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-07-20
- Volume
- 8
- Issue
- 348
- Pages
- 348ra96-348ra96
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2503767557
- Cited by
- 575
- References
- 59
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 81 · 2023: 54 · 2022: 92 · 2021: 67 · 2020: 54 · 2019: 43 · 2018: 23 · 2017: 31 · 2016: 6
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swebilius Foundation
- UCB Pharma
- Swedish Research Council
- National Center for Advancing Translational Science (UL1 TR000142)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- synaptic density, SV2A, positron emission tomography, presynaptic terminals, synaptophysin, temporal lobe epilepsy, synaptic loss, Alzheimer's disease, neuroimaging
- MeSH terms
- Adult, Aged, Brain, Epilepsy, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Synapses, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.